Compounded Tirzepatide: The 2026 Rules, Explained

First the disclosure, since the rest of the page depends on it. PeRx prescribes compounded tirzepatide with vitamin B12, made by a US 503A compounding pharmacy against each patient's own prescription. It is not Mounjaro and it is not Zepbound; those are FDA-approved Eli Lilly products, and the clinical data behind them belongs to them. Nothing here borrows that data to describe the compounded product.

The semaglutide version of this question, including the basics of what compounding is, lives at what is compounded semaglutide Read nextWhat Is Compounded Semaglutide? Is It Safe?Compounded semaglutide is the same active molecule as Ozempic and Wegovy, prepared by a licensed pharmacy for one named patient instead of manufactured under an FDA approval. That one sentence carries a lot of legal weight. This page unpacks it: what compounding is, how the compounded product differs from the brands, what changed between 2022 and 2026, and what a legitimate prescription looks like from inside a clinic that writes them.Read article . Tirzepatide has had the rougher year: its shortage ended first, the manufacturer sued first, and a court has now said more about how it may be sold.

What It Is, and What It Is Not

Tirzepatide is a single, patented 39-amino-acid peptide that activates both the GLP-1 and GIP receptors. A compounding pharmacy buys it as an active pharmaceutical ingredient from a supplier registered with the FDA, dissolves a measured amount into a sterile vial, usually with a second ingredient such as vitamin B12, and labels the vial for one named patient, working under its state board of pharmacy and USP General Chapter 797 for sterile preparations. That is the whole definition. Every other claim a seller attaches to the phrase is marketing.

Three things it is not. Not FDA approved: no compounded drug is, because approval attaches to a specific finished product that went through trials and inspection. Not a generic, which is an approved product shown to be bioequivalent to the brand; none exists for tirzepatide. And not a made-for-you medicine in any meaningful sense: most compounded tirzepatide comes in standard concentrations with a standard additive, and a federal court has treated the claim that such a vial is made for the individual patient as an assertion to be proven, not a description. PeRx does not make it.

Compounded Tirzepatide vs Zepbound and Mounjaro

Mounjaro was approved on May 13, 2022 for adults with type 2 diabetes. Zepbound, the same molecule under a second name, was approved on November 8, 2023 for chronic weight management. Both are once-weekly injections sold at six fixed strengths from 2.5 mg to 15 mg, in pens and, for Zepbound, in single-dose vials sold directly to self-pay patients. The compounded product shares the molecule and the route and differs in almost everything a regulator cares about.

Two rows carry the weight. Dose format is the safety difference: a pen measures for you, a vial asks you to measure, and the FDA adverse event file for compounded products is full of people who measured wrong. FDA review is the legal difference: nobody outside the pharmacy has verified that a given vial contains what its label says. And since Lilly cut its self-pay vial prices in December 2025, the cost gap has closed at the low steps; at 5 mg, PeRx and LillyDirect charge the same $399. Anyone choosing the compounded route on price alone should look at that table first.

U.S. Food & Drug Administration, Drugs@FDA: Mounjaro (tirzepatide), NDA 215866, approved May 13, 2022; Zepbound (tirzepatide), NDA 217806, approved November 8, 2023. Eli Lilly and Company. Approved strengths 2.5 mg to 15 mg per 0.5 mL. View study

Pharmaceutical Executive, December 1, 2025: "Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients." LillyDirect prices of $299 (2.5 mg), $399 (5 mg) and $449 (7.5 mg through 15 mg) per month. View study

The Shortage, Dated

Compounded tirzepatide exists at scale because of a shortage, and most arguments about whether it is still allowed come down to dates. Here they are, from primary sources.

U.S. Food & Drug Administration, "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize." Tirzepatide shortage resolution of October 2, 2024, reaffirmed December 19, 2024; 503A and 503B grace periods; essentially-a-copy criteria. View study

U.S. Food & Drug Administration, press announcement, April 30, 2026: "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List." Comment period through June 29, 2026. View study

U.S. Food & Drug Administration, press announcement, March 3, 2026: "FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s." View study

The Essentially-a-Copy Test

Section 503A bars a pharmacy from compounding, regularly or in inordinate amounts, a drug that is essentially a copy of a commercially available product. The FDA defines that as the same active ingredient, the same route, and a strength within 10 percent of a marketed one, unless the prescriber determines and documents that the compounded version contains a change producing a significant difference for the individual patient. The agency has also said it does not intend, for now, to act against a compounder filling four or fewer such prescriptions in a calendar month, a carve-out for the occasional patient rather than a business.

For a tirzepatide vial, each piece lands the same way: same ingredient, same route, and usually a strength within 10 percent of an approved step. That leaves the documented difference as the only thing between a lawful prescription and a copy. The FDA used semaglutide plus vitamin B12 as its worked example of a combination it may still consider a copy absent a documented patient-specific reason, and nothing in that logic spares tirzepatide. The B12 does not make the vial legally distinct. The prescriber's documented determination does.

U.S. Food & Drug Administration, Guidance for Industry, January 2018: "Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act." View study

One chemistry footnote belongs here, with its source attached. In 2026, scientists employed by Eli Lilly analyzed compounded tirzepatide and B12 products bought on the US market and reported a previously unidentified impurity from a reaction between tirzepatide and certain forms of B12. Its clinical effect is unknown, and the authors work for the maker of the approved product, which is a reason to read the paper carefully, not to ignore it. Ask a pharmacy which B12 form it uses and what testing it does on the finished vial.

Jordan B, Arbogast L, Clemens M, Huang L, et al. "A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications." Expert Opinion on Drug Safety, 2026. Authors affiliated with Eli Lilly and Company. PMID 42010938. View study

What Lilly Has Done About It

On April 23, 2025, Eli Lilly sued Mochi Health, Fella Health, Willow Health and Henry Meds in federal court. The complaints did not argue that compounding tirzepatide is illegal in itself. They argued the selling was deceptive: presenting mass-produced vials as made for the individual patient, implying they carried the safety record of the approved drugs, offering untested forms such as pills, and switching patients to additives and doses the brand is not approved at. In a separate National Advertising Division matter brought by Lilly, a compounding pharmacy permanently discontinued its challenged tirzepatide claims rather than defend them.

The cases have not moved in one direction. In August 2025 a federal court in Los Angeles dismissed the Willow Health case, reasoning that because the products require a prescription, Lilly could not show the marketing caused its lost sales. In April 2026 the San Francisco court in the Mochi Health case disagreed and let Lilly proceed; its order is the most specific judicial statement so far about what a seller of compounded tirzepatide may not say.

Eli Lilly and Company v. Mochi Health Corp., et al., No. 3:25-cv-03534-JSC (N.D. Cal.), Order re Motion to Dismiss the First Amended Complaint, Dkt. No. 126, filed April 20, 2026. Lanham Act and UCL claims proceed; conspiracy claim dismissed. View study

NPR, April 23, 2025: "Eli Lilly sues companies selling alternative versions of its weight loss drug." Suits against Mochi Health, Fella Health, Willow Health and Henry Meds. View study

BBB National Programs, National Advertising Division: "In NAD Challenge, Striker Pharmacy Discontinues Compounded Tirzepatide Claims." Challenge brought by Eli Lilly and Company. View study

What the Safety Record Shows

As of May 31, 2026, the FDA had received more than 730 adverse event reports tied to compounded tirzepatide, and 990 for compounded semaglutide. Many match the known side effects of the approved drugs: nausea, vomiting, diarrhea, abdominal pain, constipation. The failure specific to compounding is dosing. The FDA has documented hospitalizations from patients drawing the wrong volume, prescribers miscalculating a conversion, and doses given more often or escalated faster than the label allows, plus fraudulently labeled tirzepatide and, in one case, injection-site reactions tied to such a product.

U.S. Food & Drug Administration, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." Adverse event totals as of May 31, 2026; dosing-error and fraudulent-labeling reports. View study

Independent analyses of the same reporting system point the same way, with the standing caveat that spontaneous reports show association, not cause. A Geisinger group found 707 compounded-product reports among 81,078 GLP-1 reports from 2018 to 2024; those carried higher odds of preparation errors, contamination, manufacturing problems and hospitalization than reports on the approved drugs, though lower odds of dosing errors in that dataset. A second analysis counted 3,348 accidental-overdose reports across the class and tied the rise to online and compounding access, and a 2026 study of poison center calls found exposures climbing after the weight-management approvals, with a meaningful share involving dosing mistakes.

McCall KL, Mastro Dwyer KA, Casey RT, Samana TN, et al. "Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system." Expert Opinion on Drug Safety, 2026. PMID 40285721. View study

McIntyre RS, Kwan ATH. "Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study." Expert Opinion on Drug Safety, 2026. PMID 39552465. View study

Miller J, Miller R, Varney SM, Han D. "National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss." Journal of Medical Toxicology, 2026. PMID 41634285. View study

One more study explains the undercount. In a nationwide primary-care database covering 2021 through 2024, only 8.2 percent of patients on semaglutide or tirzepatide had compounded use documented, against surveys suggesting roughly a quarter of users got the drugs from compounders. The authors read the gap as patients obtaining compounded GLP-1s outside coordinated care, where no clinician is positioned to notice a problem. That is the strongest argument for getting it, if at all, from a clinic where a licensed provider reviews you before every refill.

Hendrix N, Velasquez EE, Pham H, Bazemore A. "Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset." Pharmacoepidemiology and Drug Safety, 2025. PMID 41024632. View study

What PeRx Prescribes

The order of events is the point. You complete an intake; a licensed provider reviews it and either prescribes or declines; your card is saved at checkout and charged only on approval; the pharmacy compounds the vial against that prescription, and it arrives with your name, the pharmacy and the prescriber on the label. There is no strength to pick at checkout, because the strength is a clinical decision, not a menu.

Tirzepatide is one of two PeRx products sold as a subscription, and the reason is the drug. Dosing is stepped, rising over months as tolerated, and a clinician needs to see how the current cycle went before deciding what the next vial should be. You get an advance notice by email and text about three days before each renewal, cancelling is a single action in your account, and multi-month discounts never apply to a GLP-1 because no one should hold three months of a stepped medication at once. Staying at a low step for a long time is covered in GLP-1 maintenance dosing and microdosing Read nextGLP-1 Microdosing: Safety, Evidence, and Maintenance"Microdosing Ozempic" went from a forum phrase to a TikTok trend to a survey statistic: as of 2026, about 15% of injectable GLP-1 users say they have tried it, and nearly half of them did it without asking a doctor. Meanwhile the person who actually reached goal weight on semaglutide or tirzepatide still gets two contradictory answers about maintenance. This page covers both: what microdosing means, why it spread, what evidence exists for sub-label doses (almost none), the difference between a prescriber-set lower dose and splitting a vial yourself, and why the dose belongs on a prescription rather than in a spreadsheet.Read article .

Who is screened out: anyone with a personal or family history of medullary thyroid carcinoma or MEN 2; anyone pregnant, breastfeeding, or planning a pregnancy within six months; and anyone whose history of pancreatitis, gallbladder disease or gastroparesis the provider judges disqualifying. Insulin or sulfonylurea users are not excluded, but those doses may need adjustment. Severe abdominal pain, especially spreading to the back, is a reason to seek care now. PeRx does not offer an oral or under-the-tongue tirzepatide.

The honest limits

PeRx's tirzepatide is not FDA approved, and no trial has tested this preparation. The outcome data belongs to Mounjaro and Zepbound and is not borrowed here. The B12 is a co-formulated ingredient and nothing more. At the 5 mg step the approved vial now costs the same as ours, so price alone is not a reason to choose us. The 503A footing depends on a prescriber-documented, patient-specific reason, and the FDA could narrow it at any time, which would end our ability to offer it. If any of those is a dealbreaker, the approved products exist, and the right move is to ask a prescriber about them.

What to Expect, Step by Step

Intake to first injection usually runs a few days. If the provider declines, nothing is charged. If the answer is yes, the vial ships overnight in cold packaging with insulin syringes and alcohol swabs. Open the box the day it arrives: the cold pack should still be cold, the solution clear, and the label should carry your name, the pharmacy and its license state, the prescriber, the concentration in mg per mL with the B12 strength listed separately, and a beyond-use date. Refrigerate upright, away from light, and never freeze.

The units arithmetic is the one skill a vial requires and a pen does not. Your prescription states a weekly dose in milligrams, the label a concentration in milligrams per milliliter, and the syringe is marked in units, where 100 units equal 1 mL. The volume you draw delivers the prescribed milligrams at that concentration, and it changes if the concentration changes between cycles. Work it through before the first dose; where to inject semaglutide and tirzepatide Read nextWhere to Inject Semaglutide and TirzepatideBoth are once-weekly subcutaneous injections, and the three standard sites are the same for each. The part that trips people up is not the site. It is that a compounded vial is not a prefilled pen, so you are drawing your own dose and reading it in syringe units. Here is the practical version.Read article has the conversion in full. Coming off Mounjaro or Zepbound, tell the provider the exact dose and date of your last pen; switching is managed by the prescriber, never in the same week as a pen dose.

Three side questions have their own pages: HSA and FSA peptide therapy Read nextCan You Use HSA or FSA for Peptide Therapy?Insurance almost never covers peptide therapy, which makes tax-advantaged health dollars the next question. Prescription peptides often qualify as a medical expense, but the deciding vote belongs to your plan administrator, not to any clinic. Here is how eligibility actually works under IRS rules, when a letter of medical necessity comes into play, and exactly what paying with an HSA or FSA card looks like at PeRx.Read article , gray-market GLP-1s vs compounded Read nextGray-Market GLP-1s vs Compounded: What Testing MissesThis page is for the person doing spreadsheet math on a $44 internet vial versus a legitimate prescription. No moralizing and no scare quotes. What the three tiers of GLP-1 supply legally are, what a certificate of analysis actually proves, what it cannot, and what each route really costs per month.Read article on prescribed vials versus internet vials, and semaglutide vs tirzepatide Read nextSemaglutide vs Tirzepatide: Which One Fits YouPeRx prescribes two compounded GLP-1 medications, one at $249 a month and one at $399. This is the decision guide we wish existed: what each molecule does, how the approved brands differ on their FDA labels, what the head-to-head research on those brands actually shows, and the questions a prescriber weighs before picking one for a specific patient.Read article on the two compounded options PeRx offers. For the GLP-1s against the rest of the catalog, read do peptides help you lose weight Read nextDo Peptides Help You Lose Weight? An Honest AnswerSome peptides genuinely help people lose weight. Most of the ones sold online do not. The line between the two is not marketing, it is drug class, and you can learn where it sits in about ten minutes. This page gives the verdict first and the reasoning after.Read article .

Common Questions